Verona Pharma 2024 respiratory therapies investor presentation

Verona Pharma presents its pipeline for innovative respiratory disease treatments, focused on its lead asset Ohtuvayre for COPD. The company highlights a strong financial position with $254.9M in cash, operating expenses of $27.2M quarterly, and access to $400M in debt facilities. Forward-looking statements address the drug's commercial potential, regulatory pathway, and company growth strategy.